About our Patient Care
SPECIALTY PHARMACY
SPINAL MUSCULAR ATROPHY
Spinal muscular atrophy (SMA) is a rare, genetic and progressive neuromuscular disorder characterized by weakness of the skeletal and respiratory muscles. SMA is caused by a missing gene that encodes the survival motor neuron (SMN) protein. The SMN protein is critical to the health and survival of the nerve cells in the spinal cord responsible for muscle contraction (motor neurons).
​
Approximately 10,000 people in the United States have SMA, which occurs in nearly 1 in 11,000 infants and is the number one genetic cause of infant death. The disease can affect any race, age or gender.
​
About our Patient Care
Our dedicated single-point-of-contact works with physician offices and patients/caregivers to facilitate prior authorizations and ensure a quick turn-around time, from receipt of referral to coordinating the shipment and delivery of the medication.
​
As part of treatment, we provide:
​
Dedicated Single Point of Contact
We provide prescribers and patients with a dedicated single-point-of-contact and a direct phone, fax and e-mail to help guide patients/caregivers through their treatment journey.
​
​
Shipping and Coordination of Care
We provide shipping and delivery from our pharmacy to site-of-care.
​
​
​
Insurance and Financial Assistance
​
We coordinate between the health insurance provider and patient/caregiver to ensure the prescribed therapy is approved. We work with site-of care facilities and other funding entities to help facilitate obtaining approval for the prescribed therapy.
​
​
24/7/365 Access to a Pharmacist
We provide prescribers and patients access to a pharmacist 24/7/365 to ensure patients are always cared for.
​
​
-
Berinert (C1 esterase inhibitor)Brand Name | Berinert Manufacturer | CSL Berhing Route of Administration | Intravenous (IV) injection Approved Indication | Treatment of acute abdominal, facial, or laryngeal HAE attacks in adult and pediatric patients Self-Administration | Yes, after training Product Website | www.berinert.com
-
Cinryze (C1 esterase inhibitor)Brand Name | Cinryze Manufacturer | Shire Route of Administration | Intravenous (IV) injection Approved Indication | Routine prophylaxis against angioedema attacks in patients with HAE Self-Administration | Yes, after training Product Website | www.cinryze.com
-
Firazyr (icatibant)Brand Name | Firazyr Manufacturer | Shire Route of Administration | Subcutaneous (SC) injection Approved Indication | Treatment of acute attacks of HAE in adults 18 years of age and older Self-Administration | Yes, after training Product Website | www.firazyr.com
-
Haegarda (C1 esterase inhibitor)Brand Name | Haegarda Manufacturer | CSL Behring Route of Administration | Subcutaneous Approved Indication | For routine prophylaxis to prevent HAE attacks in adolescent and adult patients. Self-Administration | Yes Product Website | www.haegarda.com
-
Kalbitor (ecallantide)Brand Name | Kalbitor Manufacturer | Dyax Corp Route of Administration | Subcutaneous injection Approved Indication | For routine prophylaxis to prevent HAE attacks in adolescent and adult patients. Self-Administration | No Product Website | www.kalbitor.com
-
Ruconest (C1 esterase inhibitor)Brand Name | Rocunest Manufacturer | Pharming N.V. Route of Administration | Intravenous (IV) injection Approved Indication | Treatment of acute attacks of HAE in adult and adolescent patients. Self-Administration | Yes, after training Product Website | www.ruconest.com
-
Takhzyro (lanadelumab-flyo)Brand Name | Takhzyro Manufacturer | Shire Route of Administration | Subcutaneous injection Approved Indication | Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years of age and older Self-Administration | Yes, after training Product Website | www.takhzyro.com
Supported Treatments
Partnering with Prescribers
Licensed prescribers can submit a completed enrollment form directly to our Admission team. We will begin the process and communicate with your office every step of the way.